NCT07312500Active, not recruiting
Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer
Application of Fecal DNA Methylation and Fecal Helicobacter Pylori Gastric Cancer Susceptibility Genes in Clinical Diagnosis, Treatment, and Relapse and Metastasis of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
Based on the detection technology of methylation sites in feces, combined or not combined with Helicobacter pylori gastric cancer susceptibility gene detection, an early diagnosis and detection system for gastric cancer is established, and the clinical diagnostic value of the detection system is evaluated. In addition, the study observed the association between different loci and post-treatment recurrence, metastasis, or long-term survival rate through long-term follow-up of gastric cancer patients; Follow up with individuals with benign diseases such as gastritis and healthy individuals, compare cases of gastric cancer, and compare their sample data during follow-up with controls who did not have the disease.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 21 Jun 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07312500
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Jan 2025 to the primary completion date, 1 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe heart, liver, kidney dysfunction, or mental illness.
- History of malignant tumors in the upper gastrointestinal tract.
Other
- Pregnant women.
- Those with unclear pathology.
- Those with unsatisfactory sample retention (such as insufficient sample size).
Who the study is looking for
- Age ≥ 18 years old, male or female not limited.
- Within 90 days, the gastroscopy and/or pathological results confirm the absence of gastric cancer.
- Patients must be able to fully understand the informed consent form and be able to personally sign it.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.